alirocumab

Known as: REGN727 monoclonal antibody, monoclonal antibody REGN727 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
AIMS To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The ODYSSEY COMBO I study (http://clinicaltrials.gov/show/NCT01644175) evaluated efficacy and safety of alirocumab as… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
AIMS To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
CONTEXT Despite current standard of care, many patients at high risk of cardiovascular disease (CVD) still have elevated low… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Statin intolerance limits many patients from achieving optimal low-density lipoprotein cholesterol (LDL-C… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to levels of… (More)
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate… (More)
Is this relevant?
2014
2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?